Accreditation/Credit Designation
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Texas MD Anderson Cancer Center designates this educational activity for a maximum of 14.75 AMA PRA Category 1 Credits TM . Physicians should only claim credit commensurate with the extent of their participation in the activity.
CME Certificates and Attendance Verification Certificates
Certificates awarding AMA PRA Category 1 Credit TM or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form.
Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.
Poster submission/ session:
The symposium will feature a poster session where academics and investigators from the industry present angiogenesis-related data from both clinical trials and laboratory research. Trainees are especially encouraged to present their research. Accepted posters will be displayed with ample time for viewing and discussions.
All symposium participants, including members of industry, are encouraged to present research data as part of the poster session.
the deadline for submitting poster applications is Friday, December 10, 2010.
Please check the website for more information and the submission form at www.antiangio2011.com.
Program Overview
Angiogenesis is an essential process in the growth of neoplasms and progression to metastasis. The angiogenic pathway is orchestrated by a range of pro-and anti-angiogenic factors that ultimately lead to the development of a neovascular blood supply to the tumor mass. Vascular endothelial growth factor (VEGF), which stimulates proliferation and migration of endothelial cells, plays a pivotal role in this process. For these reasons, the inhibition of VEGF and its receptor signaling system are attractive targets for therapeutic intervention. Indeed, the approval in 2004 of a neutralizing monoclonal antibody directed against VEGF-the first anti-angiogenic systemic drug to treat cancer patients -validated the notion introduced decades earlier that inhibition of tumor angiogenesis may be a valid approach to control tumor growth. This success has driven the search for new anti-angiogenic agents. For example, small-molecule multikinase inhibitors that target VEGF receptors have recently demonstrated efficacy in multiple tumor types. A number of other anti-angiogenic agents targeting an increasing variety of molecular tumor features are in clinical development. More recently, studies of powerful genetic and cell biological approaches have provided unprecedented insights into how angiogenic mediators are essential to tumor growth and metastasis. As a consequence, a number of new angiogenic molecules, such as miRNA, Tie-2, and EZH2, have emerged as promising targets.
Since its inception over 4 decades ago, investigators in the field of tumor angiogenesis research have made significant progress. Advancements in therapeutics have altered cancer treatment paradigms, and the next decade promises to be an exciting and productive time. This annual state-of-the-art Symposium is designed to continue the dialogue and interaction between research and clinical investigators by reviewing the current scientific understanding of vascular biology and angiogenesis. In addition, this symposium provides a forum for presenting the most current preclinical and clinical data on emerging anti-angiogenic agents and regimens. Strategies that inhibit angiogenesis in colorectal, breast, lung, esophageal, gastric, genitourinary, neuroendocrine, central nervous system, hepatocellular and gynecologic malignancies will be discussed. In addition, biomarkers and resistance pathways will be addressed and controversies in the field will be highlighted.
Educational Objectives
After attending the symposium, participants should be able to • Define angiogenesis and its relevance to the treatment of cancer; • Outline the rationale for the development of anti-angiogenic agents, and explain why angiogenic signaling pathways are targets for inhibition; • Summarize data from clinical trials that support the use of currently available anti-angiogenic agents as monotherapy or in combination with other therapeutic modalities. This clinical trial data will ultimately assist the healthcare provider in making appropriate clinical decisions; • Discuss safety and efficacy results from recent clinical trials of investigational anti-angiogenic agents that will lead to better quality care for the oncology patient.
Target Audience
This symposium is designed for medical, surgical, and radiation oncologists, pharmacists, other providers of cancer care (PAs, RNs, etc.), and research scientists who have an interest in the biology, diagnosis, and treatment of cancer, as well as those who diagnose and treat patients with nonmalignant vascular diseases, such as arthritis and retinal neovascularization. As new and emerging data on anti-angiogenic therapy is presented at this Symposium every year, it is necessary for this audience to be made aware of these findings so they can be utilized in their clinical practice. A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee.
Educational Methods
The full conference registration fee includes the tuition, breaks, lunches, and poster reception.
Refund/Cancellation Policy:
The registration fee, minus a $50 administrative handling fee, is refundable if a written request is received on or before January 21, 2011. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check. Although no refunds will be granted after January 21, 2011, you may transfer your registration to a colleague.
The Department of CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or the contact numbers as given on the registration form.
In case of activity cancellation, liability of the Department of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee. The Department of CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.
For additional information, contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866.
